Jazz Pharmaceuticals plc Common Stock (Ireland)

JAZZ IE00B4Q5ZN47

💰
Capitalization
Mid-cap

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

🔗
Website
Annual Performance 1
2021 2022 2023 2024 2025
-21% 22% -21% -3% -3%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
58
🙍
Insiders
11
Person Price Shares Total Published Completed
Cozadd Bruce C
 140.00
USD 		3,500
Sold 		490,000
USD 		01/10/2025 03/10/2025
Cozadd Bruce C
 131.78
USD 		2,000
Sold 		263,560
USD 		01/10/2025 01/10/2025
Cozadd Bruce C
 130.00
USD 		3,000
Sold 		390,000
USD 		02/09/2025 02/09/2025
Cozadd Bruce C
 127.23
USD 		3,000
Sold 		381,690
USD 		02/09/2025 02/09/2025
Cozadd Bruce C
CEO 		113.21
USD 		1,000
Sold 		113,210
USD 		01/08/2025 01/08/2025
Cozadd Bruce C
CEO 		110.00
USD 		500
Sold 		55,000
USD 		01/07/2025 01/07/2025
Cozadd Bruce C
CEO 		105.26
USD 		500
Sold 		52,630
USD 		01/07/2025 01/07/2025
Cozadd Bruce C
CEO 		110.00
USD 		500
Sold 		55,000
USD 		01/07/2025 01/07/2025
Cozadd Bruce C
CEO 		110.00
USD 		500
Sold 		55,000
USD 		02/06/2025 03/06/2025
Cozadd Bruce C
CEO 		110.00
USD 		500
Sold 		55,000
USD 		02/06/2025 03/06/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include Jazz Pharmaceuticals plc Common Stock (Ireland) to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
7% 9% -4% -3% 5% -18% -12%
Last 52W Low 52W High All-Time Low All-Time High β
137.32 97.78 142.02 97.78 142.02
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Mulligan Seamus 8 19,986,163.42 2,498,270.43 09/05/2025 12/05/2025
Cozadd Bruce C 23 7,308,506.45 317,761.15 01/11/2024 03/10/2025
Patil Neena M 4 2,123,400.60 530,850.15 03/05/2024 05/03/2025
Iannone Robert 4 2,041,861.29 510,465.32 05/03/2025 10/03/2025
Carr Patricia 12 1,733,513.44 144,459.45 06/03/2024 10/03/2025
Johnson Philip L 2 1,595,453.55 797,726.78 01/03/2024 05/03/2025
Gala Renee D 1 792,570.80 792,570.80 05/03/2025 05/03/2025
Pearce Samantha 1 264,699.75 264,699.75 05/03/2025 05/03/2025
Henderson Mary Elizabeth 1 152,703.00 152,703.00 06/09/2024 06/09/2024
Cook Jennifer E. 1 49,735.59 49,735.59 04/12/2023 04/12/2023
Smith Mark Douglas 1 49,735.59 49,735.59 04/12/2023 04/12/2023

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.